Novartis to Build Radioligand Therapy Manufacturing Plant in Denton, Texas
Novartis announced plans to establish a 46,000-square-foot radioligand therapy manufacturing site in Denton, Texas, as part of its $23 billion US expansion. The facility is expected to be operational in 2028.
Novartis announced plans to establish a new 46,000-square-foot radioligand therapy manufacturing site in Denton, Texas, on February 25, 2026. The facility will be the company's fifth RLT site in the US and first manufacturing facility in Texas, marking further progress in the company's $23 billion US investment.
A subsidiary of Novartis AG, Novartis Gene Therapies Inc., will put the radioligand therapy plant in Denton, about 30 miles north of Fort Worth. The company will make cancer treatment drugs such as Pluvicto and Lutathera at the facility. Denton officials previously estimated the company's investment would total $280 million and create 150 jobs.
Construction is scheduled to begin this year, with the site expected to become fully operational in 2028. The Denton site is expected to create new Novartis jobs in bioengineering, advanced manufacturing, quality and operations, supporting economic growth in Denton and surrounding communities.
The CEO stated that RLT has the potential to revolutionize cancer care, and the addition of the fifth RLT manufacturing site in the US strengthens the company's ability to meet growing demand, building the capabilities needed to deliver these next-generation treatments with the speed and precision they require.
The Texas site will join a comprehensive Novartis RLT manufacturing network, with existing US sites in New Jersey, Indiana and California and a recently announced site to be constructed in Florida, providing RLT capacity from coast to coast. The manufacturing network has a longstanding record of enabling greater than 99% of doses to be administered on the planned day. Each dose of RLT is custom-made and time-sensitive, making proximity to patients and treatment centers critical.
The site will serve patients in the Southern US and add network capacity as RLT expands into earlier treatment lines and additional tumor types. Novartis is actively investigating the application of RLTs across cancer types and settings, with trials in prostate cancer, breast, colon, lung, brain, pancreatic and other cancers.
The company broke ground on 4 new manufacturing and R&D facilities, initiated 3 facility expansions, and announced 2 additional sites in the last 10 months, rapidly making progress on its commitment to expand its US operations.